Cyclerion Therapeutics (CYCN) Competitors $3.11 -0.01 (-0.32%) Closing price 02/18/2025 04:00 PM EasternExtended Trading$3.16 +0.05 (+1.61%) As of 02/18/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CYCN vs. BRNS, ATHE, RAPT, INKT, QTTB, ESLA, ANVS, TPST, CASI, and ITRMShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Barinthus Biotherapeutics (BRNS), Alterity Therapeutics (ATHE), RAPT Therapeutics (RAPT), MiNK Therapeutics (INKT), Q32 Bio (QTTB), Estrella Immunopharma (ESLA), Annovis Bio (ANVS), Tempest Therapeutics (TPST), CASI Pharmaceuticals (CASI), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Barinthus Biotherapeutics Alterity Therapeutics RAPT Therapeutics MiNK Therapeutics Q32 Bio Estrella Immunopharma Annovis Bio Tempest Therapeutics CASI Pharmaceuticals Iterum Therapeutics Cyclerion Therapeutics (NASDAQ:CYCN) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership. Is CYCN or BRNS more profitable? Barinthus Biotherapeutics' return on equity of -34.26% beat Cyclerion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion TherapeuticsN/A -55.32% -48.35% Barinthus Biotherapeutics N/A -34.26%-29.30% Does the MarketBeat Community favor CYCN or BRNS? Cyclerion Therapeutics received 19 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote. CompanyUnderperformOutperformCyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Barinthus BiotherapeuticsOutperform Votes15100.00% Underperform VotesNo Votes Does the media refer more to CYCN or BRNS? In the previous week, Cyclerion Therapeutics and Cyclerion Therapeutics both had 1 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 1.00 beat Cyclerion Therapeutics' score of -1.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cyclerion Therapeutics Negative Barinthus Biotherapeutics Positive Do institutionals & insiders hold more shares of CYCN or BRNS? 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 36.1% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable earnings and valuation, CYCN or BRNS? Cyclerion Therapeutics has higher revenue and earnings than Barinthus Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$1.62M5.20-$5.26MN/AN/ABarinthus Biotherapeutics$800K54.31-$73.35M-$1.49-0.72 Do analysts prefer CYCN or BRNS? Barinthus Biotherapeutics has a consensus target price of $5.17, indicating a potential upside of 378.40%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, CYCN or BRNS? Cyclerion Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.82, meaning that its share price is 182% less volatile than the S&P 500. SummaryBarinthus Biotherapeutics beats Cyclerion Therapeutics on 8 of the 14 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.43M$6.91B$5.80B$9.22BDividend YieldN/A2.89%5.27%3.98%P/E RatioN/A3.3518.7915.83Price / Sales5.20352.99479.0583.70Price / CashN/A75.6346.0538.28Price / Book0.675.547.145.01Net Income-$5.26M$164.55M$3.20B$220.98M7 Day Performance-7.44%1.73%1.38%2.13%1 Month Performance4.01%1.38%3.47%1.63%1 Year Performance7.24%-0.12%20.17%16.41% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics0.9726 of 5 stars$3.11-0.3%N/A+7.3%$8.43M$1.62M0.0030Negative NewsBRNSBarinthus Biotherapeutics3.4984 of 5 stars$1.01-1.9%$5.17+411.6%-57.0%$40.63M$800,000.00-0.68107Positive NewsATHEAlterity Therapeutics1.6042 of 5 stars$4.62+8.7%$8.00+73.2%+101.5%$40.38MN/A0.0010Gap UpRAPTRAPT Therapeutics4.3749 of 5 stars$1.15-0.9%$9.56+730.9%-95.4%$40.20M$1.53M-0.4280News CoveragePositive NewsINKTMiNK Therapeutics2.6149 of 5 stars$9.96-11.0%$65.00+552.6%+8.3%$39.44MN/A-2.5530QTTBQ32 Bio2.7871 of 5 stars$3.18+1.0%$29.86+838.9%N/A$38.73M$1.16M-0.2239ESLAEstrella Immunopharma3.1566 of 5 stars$1.07-4.5%N/A+27.7%$38.71MN/A-4.12N/AAnalyst ForecastPositive NewsGap UpANVSAnnovis Bio2.5931 of 5 stars$2.71-7.7%$31.40+1,057.0%-76.2%$38.65MN/A-0.613Short Interest ↓TPSTTempest Therapeutics3.1731 of 5 stars$0.88+0.3%$21.67+2,364.1%-75.5%$38.37MN/A-0.5720High Trading VolumeCASICASI Pharmaceuticals4.0547 of 5 stars$2.47+0.4%$6.00+142.9%-56.4%$38.26M$33.88M-1.11180Gap UpITRMIterum Therapeutics2.8348 of 5 stars$1.39-2.8%$5.00+259.7%+0.7%$38.25MN/A-0.7010Short Interest ↓ Related Companies and Tools Related Companies BRNS Competitors ATHE Competitors RAPT Competitors INKT Competitors QTTB Competitors ESLA Competitors ANVS Competitors TPST Competitors CASI Competitors ITRM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYCN) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.